Squalenoylation: A generic platform for nanoparticular drug delivery

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 609-618

  Desmaële, Didier ^a   Gref, Ruxandra ^a   Couvreur, Patrick ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Anticancer activity; Antiviral activity; Nanoassemblies; Nucleosidic analogues; Paclitaxel; Squalenoylation

Indexed keywords

ANTICANCER ACTIVITIES; ANTIVIRAL ACTIVITIES; NANO-ASSEMBLIES; NUCLEOSIDIC ANALOGUES; PACLITAXEL; SQUALENOYLATION;

BIOCHEMISTRY; PLATINUM COMPOUNDS;

DRUG DELIVERY;

1,1'',2 TRISNOR SQUALENIC ACID; CHLOROFORMIC ACID ETHYL ESTER; CISPLATIN; CYTIDINE DERIVATIVE; DIDANOSINE; GEMCITABINE; HYDROGEN PEROXIDE; N HYDROXYSUCCINIMIDYL ESTER; NANOCARRIER; PACLITAXEL; SQUALENE; SUCCINIMIDE DERIVATIVE; UNCLASSIFIED DRUG; ZALCITABINE;

ACYLATION; CANCER CELL CULTURE; CHEMICAL STRUCTURE; COMPLEX FORMATION; DEPROTECTION REACTION; DISPERSION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG OXIDATION; DRUG RELEASE; DRUG SCREENING; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SQUALENOYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DIDANOSINE; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; SQUALENE; ZALCITABINE;

EID: 84862676788     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.07.038     Document Type: Review

References (72)

1. G. Ourisson, M. Rhomer, K. Poralla, Prokaryotic hopanoids and other polyterpenoids sterol surrogates, Ann. Rev. Microbiol. 41 (1987) 301-333.
2. T. Bosak, R.M. Losick, A. Pearson, A polycyclic terpenoid that alleviates oxidative stress, Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 6725-9729.
3. Z.-R. Huang, Y.-K. Lin, J.-Y. Fang, Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology, Molecules 14 (2009) 540-554.
4. T.A. Miettinen, H. Vanhanen, Serum concentration and metabolism of cholesterol during rapeseed oil and squalene feeding, Am. J. Clin. Nutr. 59 (1994) 356-363.
5. H. Gylling, T.A. Miettinen, Post absorptive metabolism of dietary squalene, Atherosclerosis 106 (1994) 169-178.
6. J. Ernst, W.S. Sheldrick, J.-H. Fuhrhop, The crystal structure of squalene, Angew. Chem. Int. Ed Engl. 15 (1976) 778.
7. E.E. van Tamelen, Bioorganic chemistry: sterol and acyclic terpene terminal epoxides, Acc. Chem. Res. (1968) 111-120.
8. A. Eschenmoser, L. Ruzicka, O. Jeger, D. Arigoni, Triterpenes. CXC. A stereochemical interpretation of the biogenetic isoprene rule of the triterpenes, Helv. Chim. Acta 38 (1955) 1890-1904.
9. G. Stork, A.W. Burgstahler, The stereochemistry of polyene cyclization, J. Am. Chem. Soc. 77 (1955) 5068-5077.
10. L. Pogliani, M. Ceruti, G. Ricchiardi, D. Viterbo, An NMR and molecular mechanics study of squalene and squalene derivatives, Chem. Phys. Lipids 70 (1994) 21-34.
11. L. Pogliani, M. Milanesio, M. Ceruti, D. Viterbo, Conformational and dynamical study of squalene derivatives. III: Azasqualenes and solvated squalene, Chem. Phys. Lipids 103 (1999) 81-93.
12. J.M. Brown, D.R.M. Martens, An assessment of the mobility of squalene in part-aqueous solutions from carbon magnetic resonance spin-lattice relaxation times: comparison with squalene and 2,3-dihydroxy-2,3-dihydrosqualene, Tetrahedron 33 (1977) 931-935.
13. A. Laza-Knoerr, N. Huang, J.L. Grossiord, P. Couvreur, R. Gref, Interfacial rheology as a tool to study the potential of cyclodextrin polymers to stabilize oil-water interfaces, J. Incl. Phenom. Macrocycl. Chem. 69 (2011) 475-479.
14. T. Tadrosa, P. Izquierdob, J. Esquenab, C. Solans, Formation and stability of nanoemulsions, Adv. Colloid Interface Sci. 108-109 (2004) 303-318.
15. C.B. Fox, R.C. Anderson, T.S. Dutill, Y. Goto, S.G. Reed, T.S. Vedvick, Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions, Colloids Surf. B Biointerfaces 65 (2008) 98-105.
16. C.B. Fox, Squalene emulsions for parenteral vaccine and drug delivery, Molecules 14 (2009) 3286-3312.
17. J.J. Wang, K.C. Sung, C.H. Yeh, J.Y. Fang, The delivery and antinociceptive effects of morphine and its ester prodrugs from lipid emulsions, Int. J. Pharm. 353 (2008) 95-104.
18. J.J. Wang, K.C. Sung, O.Y. Hu, C.H. Yeh, J.Y. Fang, Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs, J. Control. Release 115 (2006) 140-149.
19. J.Y. Fang, C.L. Fang, C.H. Liu, Y.H. Su, Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC), Eur. J. Pharm. Biopharm. 70 (2008) 633-640.
20. R.L. Alexander, G.L. Kucera, Lipid nucleoside conjugates for the treatment of cancer, Curr. Pharm. Des. 11 (2005) 1079-1089.
21. A.M. Bergman, C.M. Kuiper, D.A. Voorn, E.M. Comijn, F. Myhren, M.L. Sandvold, H.R. Hendriks, G.J. Peters, Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines, Biochem. Pharmacol. 67 (2004) 503-511.
22. S.M. Ali, A.R. Khan, M.U. Ahmad, P. Chen, S. Sheikh, I. Ahmad, Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002), Bioorg. Med. Chem. Lett. 15 (2005) 2571-2574.
23. P. Chen, P.Y. Chien, A.R. Khan, S. Sheikh, S.M. Ali, M.U. Ahmad, I. Ahmad, In-vitro and in-vivo anti-cancer activity of a novel gemcitabine- cardiolipin conjugate, Anticancer Drugs 17 (2006) 53-61.
24. A.D. Adema, M. Radi, J. Daft, J. Narayanasamy, E.K. Hoebe, L.E. Alexander, C.K. Chu, G.J. Peters, Troxacitabine prodrugs for pancreatic cancer, Nucleosides Nucleotides Nucleic Acids 26 (2007) 1073-1077.
25. P. Couvreur, B. Stella, L. Cattel, F. Rocco, J.-M. Renoir, V. Rosilio, Nanoparticules de dérivés de la gemcitabine, 2006 (WO/2006/090029).
26. M. Payne, P. Ellis, D. Dunlop, M. Ranson, S. Danson, L. Schacter, D. Talbot, DHApaclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial, J. Thorac. Oncol. 1 (2006) 984-990.
27. R.J. Jones, R.E. Hawkins, M.M. Eatock, D.R. Ferry, F.A. Eskens, H. Wilke, T.R. Evans, A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma, Cancer Chemother. Pharmacol. 61 (2008) 435-441.
28. S. Dueland, S. Aamdal, M.J. Lind, H. Thomas, M.L. Sandvold, J.M. Gaullier, W. Rasch, Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study, Acta Oncol. 48 (2009) 137-145.
29. P. Couvreur, B. Stella, L.H. Reddy, H. Hillaireau, C. Dubernet, D. Desmaële, S. Lepêtre-Mouelhi, F. Rocco, N. Dereuddre-Bosquet, P. Clayette, V. Rosilio, V. Marsaud, J.M. Renoir, L. Cattel, Squalenoyl nanomedicines as potential therapeutics, Nano Lett. 6 (2006) 2544-2548.
30. P. Couvreur, L.H. Reddy, S. Mangenot, J.H. Poupaert, D. Desmaele, S. Lepetre-Mouelhi, B. Pili, C. Bourgaux, H. Amenitsch, M. Ollivon, Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue, Small 4 (2008) 247-253.
31. M. Ceruti, F. Viola, G. Balliano, P. Milla, G. Roma, G. Grossi, F. Rocco, Synthesis of (E)- and (Z)-29-methylidyne-2,3-oxidosqualene derivatives as inhibitors of liver and yeast oxidosqualene cyclase, J. Chem. Soc. Perkin 1 (2002) 1477-1486.
32. H.A.J. Aerts, B.F.E. Sels, P.A. Jacobs, The use of 1H NMR for yield determination in the regioselective epoxidation of squalene, J. Am. Oil Chem. Soc. 82 (2005) 409-413.
33. L. D'Accolti, C. Annese, C. Fusco, Direct regio- and stereoselective synthesis of squalene 2,3;22,23-dioxide using dioxiranes, Tetrahedron Lett. 46 (2005) 8459-8462.
34. E.J. Corey, M.C. Noe, S. Lin, Mechanistically designed bis-cinchona alkaloid ligand allows position- andenantioselective dihydroxylation of farnesol and other oligoprenyl derivatives at the terminal isopropylidene unit, Tetrahedron Lett. 36 (1995) 8741-8744.
35. S.S. Sen, G.D. Prestwich, Trisnorsqualene alcohol, a potent inhibitor of vertebrate squalene epoxidase, J. Am. Chem. Soc. 111 (1989) 1508-1510.
36. J. Caron, H.L. Reddy, S. Lepêtre-Mouelhi, S. Wack, P. Clayette, C. Rogez-Kreuz, R. Yousfi, P. Couvreur, D. Desmaële, Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues, Bioorg. Med. Chem. Lett. 20 (2010) 2761-2764.
37. J. Caron, E. Lepeltier, L.H. Reddy, S. Lepêtre-Mouelhi, S. Wack, C. Bourgaux, P. Couvreur, D. Desmaële, Squalenoyl gemcitabine monophosphate: synthesis, nanoassemblies characterisation and biological evaluation, Eur. J. Org. Chem. 14 (2011) 2615-2628.
38. F. Dosio, L.H. Reddy, A. Ferrero, B. Stella, L. Cattel, P. Couvreur, Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis characterization, and biological evaluation, Bioconjug. Chem. 21 (2010) 1349-1361.
39. K.R. Barnes, A. Kutikov, S.J. Lippard, Synthesis, characterisation, and cytotoxicity of a series of estrogen-tethered platinum (IV) complexes, Chem. Biol. 11 (2004) 557-564.
40. M.R. Reithofer, S.M. Valiahdi, M.A. Jakupec, V.B. Arion, A. Egger, M. Galanski, B.K. Keppler, Novel di- and tetracarbocylatoplatinum (IV) complexes, synthesis, characterisation, cytotoxic activity, andDNAplatination, J.Med. Chem. 50 (2007) 6692-6699.
41. J.L. Arias, L. Harivardhan Reddy, M. Othman, B. Gillet, D. Desmaële, F. Zouhiri, F. Dosio, R. Gref, P. Couvreur, Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics, ACS Nano 13 (2011) 1513-1521.
42. F. Bekkara-Aounallah, R. Gref, M. Othman, L.H. Reddy, B. Pili, V. Allain, C. Bourgaux, H. Hillaireau, S. Lepêtre-Mouelhi, D. Desmaële, J. Nicolas, N. Chafi, P. Couvreur, Novel PEGylated nanoassemblies made of self-assembled squalenoyl nucleoside analogues, Adv. Funct. Mater. 18 (2008) 3715-3725.
43. C. Oussoren, M. Magnani, A. Fraternale, A. Casabianca, L. Chiar-antini, R. Ingebringsten, W.J.M. Underberg, G. Storm, Liposomes as carriers of the antiretroviral agent dideoxycytidine-5′-triphosphate, Int. J. Pharm. 180 (1999) 261-270.
44. M.L. Immordino, P. Brusa, F. Rocco, S. Arpicco, M. Ceruti, L. Cattel, Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs, J. Control. Release 100 (2004) 331-346.
45. L. Bildstein, H. Hillaireau, D. Desmaële, S. Lepêtre-Mouelhi, C. Dubernet, P. Couvreur, Freeze-drying of squalenoylated nucleoside analogue nanoparticles, Int. J. Pharm. 381 (2009) 140-145.
46. A. Sharma, R.M. Straubinger, Novel taxol formulations-preparation and characterization of taxol-containing liposomes, Pharm. Res. 11 (1994) 889-896.
47. P.P. Constantinides, K.J. Lambert, A.K. Tustian, B. Schneider, S. Lalji, W.W. Ma, B. Wentzel, D. Kessler, D. Worah, S.C. Quay, Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel, Pharm. Res. 17 (2000) 175-182.
48. N.K. Ibrahim, N. Desai, S. Legha, P. Soon-Shiong, R.L. Theriault, E. Rivera, B. Esmaeli, S.E. Ring, A. Bedikian, G.N. Hortobagyi, J.A. Ellerhorst, Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel, Clin. Cancer Res. 8 (2002) 1038-1044.
49. A. Ambike, V. Rosilio, B. Stella, S. Lepêtre-Mouelhi, P. Couvreur, Interaction of self-assembled squalenoyl Gemcitabine nanoparticles with phospholipid cholesterol monolayers mimicking a biomembrane, Langmuir 27 (2011) 4891-4899.
50. L. Bildstein, V. Marsaud, H. Chacun, S. Lepêtre-Mouelhi, D. Desmaële, P. Couvreur, C. Dubernet, Extracellular-protein-enhanced cellular uptake of squalenoyl gemcitabine from nanoassemblies, Soft Matter 6 (2010) 5570-5580.
51. B. Pili, C. Bourgaux, H. Amenitsch, G. Keller, S. Lepêtre-Mouelhi, D. Desmaële, P. Couvreur, M. Ollivon, Interaction of a new anticancer prodrug, gemcitabine-squalene, with a model membrane: coupled DSC and XRD study, Biochim. Biophys. Acta, Biomembr. 1798 (2010) 1522-1532.
52. L. Bildstein, C. Dubernet, V. Marsaud, H. Chacun, V. Nicolas, C. Gueutin, A. Sarasin, H. Bénech, S. Lepêtre-Mouelhi, D. Desmaële, P. Couvreur, Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway, J. Control. Release 147 (2010) 163-170.
53. J.R. Mackey, R.S. Mani, M. Selner, D. Mowles, J.D. Young, J.S. Belt, C.R. Crawford, C.E. Cass, Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines, Cancer Res. 58 (1998) 4349-4357.
54. T. Neff, C.A. Blau, Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine, Exp. Hematol. 24 (1996) 1340-1346.
55. J.L. Abbruzzese, R. Grunewald, E.A. Weeks, D. Gravel, T. Adams, B. Nowak, S. Mineishi, P. Tarassoff, W. Satterlee, M.N. Raber, A phase 1 clinical, plasma, and cellular pharmacology study of gemcitabine, J. Clin. Oncol. 9 (1991) 491-498.
56. M.Y. Kim, D.H. Ives, Human deoxycytidine kinase: kinetic mechanism and end product regulation, Biochemistry 28 (1989) 9043-9047.
57. B. Ullman, Dideoxycytidine metabolism in wild type and mutant CEM cells deficient in nucleoside transport or deoxycytidine kinase, Adv. Exp. Med. Biol. 253B (1989) 415-420.
58. L.H. Reddy, C. Dubernet, S. Lepêtre-Mouelhi, P.E. Marque, D. Desmaële, P. Couvreur, A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types, J. Control. Release 124 (2007) 20-27.
59. L.H. Reddy, J.M. Renoir, V. Marsaud, S. Lepetre-Mouelhi, D. Desmaële, P. Couvreur, Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor, Mol. Pharm. 6 (2009) 1526-1535.
60. R.B. Dye, S.P. Fink, R.C. Williams, Taxol-induced flexibility of microtubules and its reversal by MAP-2 and Tau, J. Biol. Chem. 268 (1993) 6847-6850.
61. M.O. Bradley, N.L. Webb, F.H. Anthony, P. Devanesan, P.A. Witman, S. Hemamalini, M.C. Chander, S.D. Baker, L.F. He, S.B. Horwitz, C.S. Swindell, Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel, Clin. Cancer Res. 7 (2001) 3229-3238.
62. H. Khoury, A. Deroussent, L.H. Reddy, P. Couvreur, G. Vassal, A. Paci, Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography-tandem mass spectrometry in human plasma, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 858 (2007) 71-78.
63. L.H. Reddy, H. Khoury, A. Paci, A. Deroussent, H. Ferreira, C. Dubernet, X. Decleves, M. Besnard, H. Chacun, S. Lepêtre-Mouelhi, D. Desmaële, B. Rousseau, C. Laugier, J.C. Cintrat, G. Vassal, P. Couvreur, Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice, Drug Metab. Dispos. 36 (2008) 1570-1577.
64. P.V.I. Koivisto, T.A. Miettinen, Increased amount of cholesterol precursors in lipoproteins after ileal exclusion, Lipids 23 (1988) 993-996.
65. H. Relas, H. Gylling, T.A. Miettinen, Fate of intravenously administered squalene and plant sterols in human subjects, J. Lipid Res. 42 (2001) 988-994.
66. L.H. Reddy, P.E. Marque, C. Dubernet, S. Lepêtre-Mouelhi, D. Desmaële, P. Couvreur, Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine, J. Pharmacol. Exp. Ther. 325 (2008) 484-490.
67. S. Réjiba, L.H. Reddy, C. Parmentier, C. Bigand, P. Couvreur, A. Hajri, Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer, Nanomedicine, doi:10.1016/j.nano.2011. 02.012.
68. G.S. Kelly, Squalene and its potential clinical uses, Alt. Med. Rev. 4 (1999) 29-36.
69. L.H. Reddy, H. Ferreira, C. Dubernet, S. Lepêtre-Mouelhi, D. Desmaële, B. Rousseau, P. Couvreur, Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms, Anticancer Drugs 19 (2008) 999-1006.
70. L.H. Reddy, H. Ferreira, C. Dubernet, S.L. Mouelhi, D. Desmaële, B. Rousseau, P. Couvreur, Oral absorption and tissue distribution of a new squalenoyl anticancer nanomedicine, J. Nanopart. Res. 10 (2008) 887-891.
71. L. Arias, L.H. Reddy, P. Couvreur, Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting, Langmuir 24 (2008) 7512-7519.
72. M. Othman, D. Desmaële, P. Couvreur, L. Van der Elst, S. Laurent, R.N. Muller, C. Bourgaux, E.Morvan, T. Pouget, S. Lepêtre-Mouelhi, P. Durand, R. Gref, Synthesis and physicochemical characterization of new squalenoyl amphiphilic gadolinium complexes as nanoparticle contrast agents, Org. Biomol. Chem. 9 (2011) 4367-4386.